‘Pradaxa 75mg’ approval voluntarily withdrawn due to insufficient usage

Boehringer Ingelheim was confirmed to voluntarily withdraw Korean approval of the low volume of its novel oral anticoagulant, ‘Pradaxa(generic name: dabigatran).’ It has been a year since it acquired the approval on August last year.

Thus, Pradaxa 75mg returned the ‘Venous Thromboembolism Prevention for Hip or Knee Arthroplasty Patients’ indication to the government.

According to a confirmed ...